Building a Genetic and Clinical Information Database for Cancer Research
Collects tumor samples, blood and clinical records from adults with cancer to find biomarkers.
Key facts
- Who runs it
- Samsung Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Development and Utilization of an Integrated Clinical Genomic Database
- Status
- Recruiting
- People taking part
- 118,750 people, planned
- Started
- 6 Dec 2024
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 4 groups
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer or suspected cancer, and for people having routine health screening at Samsung Medical Center. Leftover samples and extra blood samples are collected for a genetic and clinical database.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Diagnosed or suspected cancer. Stored samples from patients with gastric, colorectal, liver, pancreatic, biliary tract, lung, breast, esophageal, blood or kidney cancers may also be used.
Main reasons for not taking part
- The investigator judges the person unsuitable to take part
- Withdrawing consent after joining
- Earlier research participants whose sample storage period has ended
- Earlier research participants who did not agree to later use of their samples
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 19 years or older
- Patients diagnosed with or suspected of having cancer who are scheduled to undergo tissue collection for diagnostic, surgical, or therapeutic purposes
- Individuals undergoing routine health screening at Samsung Medical Center who voluntarily provide informed consent to participate in the study
- Patients who voluntarily provide informed consent to participate in the study, including consent for genetic analysis
- Individuals whose previously collected tissue or blood specimens are available through the Samsung Medical Center Biobank, including specimens from patients with gastric, colorectal, liver, pancreatic, biliary tract, lung, breast, esophageal, hematologic, or kidney cancers, in accordance with applicable consent and ethical requirements
- Participants previously enrolled in an approved research study (IRB File No. 2020-02-015) whose stored biospecimens remain within the approved retention period and for whom consent for secondary use has been obtained. Additional consent is not required for these specimens when permitted under the approved protocol
Who cannot take part
- Participants from previously approved research studies whose biospecimen retention period has expired or who did not consent to secondary use of their specimens
- Individuals considered unsuitable for study participation at the investigator's discretion
- Participants who withdraw their consent after enrollment
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaContact: Kyung Han Na, RNTaking people
About the trial
What the trial wants to find out
This observational study aims to develop an integrated genomic and clinical database to support the discovery and validation of biomarkers for cancer diagnosis, treatment selection, and prediction of treatment response.
Read full original descriptionShow less
The study will include adults aged 19 years or older with diagnosed or suspected cancer, as well as consenting individuals undergoing routine health screenings at Samsung Medical Center. Researchers will collect residual tissue specimens obtained during routine diagnostic or therapeutic procedures and additional blood samples collected alongside routine clinical blood tests. Previously collected specimens from approved biobank resources may also be used.
Genetic, molecular, and protein analyses will be performed on the collected specimens, and the results will be integrated with clinical information, including cancer diagnosis, treatment history, treatment response, and disease outcomes. Patient-derived organoids and immune cells may also be used to investigate drug responses in laboratory models.
The study aims to identify biomarkers associated with cancer development, progression, and treatment response, and to support the development of diagnostic tools and personalized treatment strategies.
No experimental treatments will be assigned as part of this study, and no additional tissue biopsies will be performed solely for research purposes.
The 4 groups in the trial
- IM6
Hematology-Oncology
- IM1
Gastroenterology
- OP
Surgery
- RT
Radiation Oncology
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Development and Utilization of a Comprehensive Genetic-Clinical Database
- Plain-language title
- Building a Genetic and Clinical Information Database for Cancer ResearchGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 November 2026